Brooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
Key highlights
- Board approved unaudited standalone and consolidated results for quarter and half year ended 30 Sep 2026 on 07 Nov 2026
- Half-year consolidated profit before tax ₹71.14 crore; exceptional gain of ₹74.70 crore on partial divestment (11.48%) of Brooks Steriscience Ltd
- Total assets stood at ₹2,177.03 crore as of 30 Sep 2026; cash and cash equivalents at ₹0.71 crore, down from ₹6.59 crore at 31 Mar 2026
Original filing
Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Brooks Laboratories
- Financial resultsBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- Acquisition / mergerNotableBrooks Laboratories Limited approves scheme to demerge manufacturing business
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
- Kilitch Drugs (India) approves unaudited Q2 and half-year results to 30 Sept 2026
- Mangalam Seeds approves Q2 results, divests subsidiary and associate stakes
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.